The Association Between Serum Levels of Leptin and Lipid Profiles in Cardiovascular Patients With Valve Calcification
Adipose tissue-derived hormones known as adipokines, like leptin, have multiple bioactions. Notwithstanding the key roles of leptin in regulating energy homeostasis and metabolism, its cardiovascular functions are complex and not fully understood. This study aimed to investigate the association between serum concentrations of leptin and lipid profiles in patients with valve calcification. Seventy-two patients with valve calcification and 72 healthy individuals participated in this case-control study. The serum levels of biochemical markers and leptin were measured by the standard enzymatic methods and enzyme-linked immunosorbent assay (ELISA) technique, respectively. Significantly increased serum concentrations of FBS (P=0.001), urea (P<0.0001), creatinine (P=0.018), P (P<0.0001), LDL-C (P=0.011) and lower Ca (P=0.006), and HDL-C (P<0.0001) levels were observed in patients compared to controls. There was no significant difference in the serum level of TG and TC of patients than controls. Systolic and diastolic blood pressures were significantly increased in patients relative to controls (P<0.0001). However, a significantly diminished serum level of leptin was observed in patients than controls (P<0.0001). The correlation analysis demonstrated that the serum leptin concentration is negatively correlated with creatinine, but it is positively correlated with systolic blood pressure (P=0.0302, P=0.0362, respectively). There was no statistically significant association between serum levels of leptin and lipid profiles. Our findings indicated dyslipidemia and reduced serum leptin concentrations in patients with valve calcification, suggesting the role of lipid abnormalities and reduced leptin levels in the development and pathogenesis of valve calcification diseases.
2. Chester AH. Molecular and cellular mechanisms of valve calcification. Aswan Hear Cent Sci Pract Ser 2011;2011(1):4.
3. Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, et al. Calcific Aortic Valve Disease: Not Simply a Degenerative Process A Review and Agenda for Research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Circulation 2011;124(16):1783–91.
4. Abramowitz Y, Jilaihawi H, Chakravarty T, Mack MJ, Makkar RR. Mitral Annulus Calcification. J Am Coll Cardiol 2015;66(17):1934–41.
5. WHO Scientific Group on the Burden of Musculoskeletal Conditions at the Start of the New Millennium. The burden of musculoskeletal conditions at the start of the new millennium. World Health Organ Tech Rep Ser 2003;919:i–x, 1-218, back cover.
6. Deal CL. Osteoporosis: prevention, diagnosis, and management. Am J Med 1997;102(1A):35S–39S.
7. Lozano J V., Pallarés V, Cea-Calvo L, Llisterri JL, Fernández-Pérez C, Martí-Canales JC, et al. Serum lipid profiles and their relationship to cardiovascular disease in the elderly: the PREV-ICTUS study. Curr Med Res Opin 2008;24(3):659–70.
8. Sood A, Shore SA. Adiponectin, Leptin, and Resistin in Asthma: Basic Mechanisms through Population Studies. J Allergy 2013;2013:785835.
9. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11(2):85–97.
10. Kiguchi N, Maeda T, Kobayashi Y, Fukazawa Y, Kishioka S. Leptin enhances CC-chemokine ligand expression in cultured murine macrophage. Biochem Biophys Res Commun 2009;384(3):311–5.
11. Santos-Alvarez J, Goberna R, Sánchez-Margalet V. Human Leptin Stimulates Proliferation and Activation of Human Circulating Monocytes. Cell Immunol 1999;194(1):6–11.
12. Blum WF, Englaro P, Hanitsch S, Juul A, Hertel NT, Müller J, et al. Plasma Leptin Levels in Healthy Children and Adolescents: Dependence on Body Mass Index, Body Fat Mass, Gender, Pubertal Stage, and Testosterone. J Clin Endocrinol Metab 1997;82(9):2904–10.
13. Lieb W, Sullivan LM, Harris TB, Roubenoff R, Benjamin EJ, Levy D, et al. Plasma Leptin Levels and Incidence of Heart Failure, Cardiovascular Disease, and Total Mortality in Elderly Individuals. Diabetes Care 2009;32(4):612–6.
14. Rosa M, Paris C, Sottejeau Y, Corseaux D, Robin E, Tagzirt M, et al. Leptin induces osteoblast differentiation of human valvular interstitial cells via the Akt and ERK pathways. Acta Diabetol 2017;54(6):551–60.
15. Elkalioubie A, Zawadzki C, Roma-Lavisse C, Chinetti-Gbaguidi G, Tagzirt M, Corseaux D, et al. Free leptin, carotid plaque phenotype and relevance to related symptomatology: Insights from the OPAL-Lille carotid endarterectomy study. Int J Cardiol 2013;168(5):4879–81.
16. Payne GA, Kohr MC, Tune JD. Epicardial perivascular adipose tissue as a therapeutic target in obesity-related coronary artery disease. Br J Pharmacol 2012;165(3):659–69.
17. Zeng R, Xu C-H, Xu Y-N, Wang Y-L, Wang M. Association of leptin levels with pathogenetic risk of coronary heart disease and stroke: a meta-analysis. Arq Bras Endocrinol Metabol 2014;58(8):817–23.
18. Bigalke B, Stellos K, Geisler T, Seizer P, Mozes V, Gawaz M. High plasma levels of adipocytokines are associated with platelet activation in patients with coronary artery disease. Platelets 2010;21(1):11–9.
19. Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999;48(2):426–9.
20. Chiba T, Shinozaki S, Nakazawa T, Kawakami A, Ai M, Kaneko E, et al. Leptin deficiency suppresses progression of atherosclerosis in apoE-deficient mice. Atherosclerosis 2008;196(1):68–75.
21. Zeadin M, Butcher M, Werstuck G, Khan M, Yee CK, Shaughnessy SG. Effect of leptin on vascular calcification in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2009;29(12):2069–75.
22. Saber H, Himali JJ, Shoamanesh A, Beiser A, Pikula A, Harris TB, et al. Serum Leptin Levels and the Risk of Stroke. Stroke 2015;46(10):2881–5.
23. Martin SS, Blaha MJ, Muse ED, Qasim AN, Reilly MP, Blumenthal RS, et al. Leptin and incident cardiovascular disease: the Multi-ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2015;239(1):67–72.
24. Seven E, Husemoen LLN, Sehested TSG, Ibsen H, Wachtell K, Linneberg A, et al. Adipocytokines, C-Reactive Protein, and Cardiovascular Disease: A Population-Based Prospective Study. PLoS One 2015;10(6):e0128987.
25. Efstratiadis G, Nikolaidou C, Vergoulas G. Leptin as a cardiovascular risk factor. Hippokratia 2007;11(4):163–70.
26. Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL. Leptin Enhances the Calcification of Vascular Cells. Circ Res 2001;88(9):954–60.
27. Hasty AH, Shimano H, Osuga J, Namatame I, Takahashi A, Yahagi N, et al. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J Biol Chem 2001;276(40):37402–8.
28. Piemonti L, Calori G, Mercalli A, Lattuada G, Monti P, Garancini MP, et al. Fasting Plasma Leptin, Tumor Necrosis Factor-Receptor 2, and Monocyte Chemoattracting Protein 1 Concentration in a Population of Glucose-Tolerant and Glucose-Intolerant Women: Impact on cardiovascular mortality. Diabetes Care 2003;26(10):2883–9.
29. Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation 2008;117(25):3238–49.
Copyright (c) 2020 Acta Medica Iranica
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.